MYL5 as a Novel Prognostic Marker is Associated with Immune Infiltrating in Breast Cancer: A Preliminary Study

Table 1

Correlation between different clinicopathological factors and the expression of MYL5 gene in BRCA from TCGA database.

MYL5	Low expression			High expression		Statistic	Method
n		541	542
T stage, n (%)					<0.001	20.59	Chi-squared.test
T1		114 (10.6%)	163 (15.1%)
T2		347 (32.1%)	282 (26.1%)
T3		58 (5.4%)	81 (7.5%)
T4		21 (1.9%)	14 (1.3%)
N stage, n (%)					0.083	6.68	Chi-squared.test
N0		260 (24.4%)	254 (23.9%)
N1		167 (15.7%)	191 (18%)
N2		69 (6.5%)	47 (4.4%)
N3		34 (3.2%)	42 (3.9%)
M stage, n (%)					1.000	0	Chi-squared.test
M0		478 (51.8%)	424 (46%)
M1		11 (1.2%)	9 (1%)
Pathologic stage, n (%)					0.040	8.33	Chi-squared.test
Stage I		73 (6.9%)	108 (10.2%)
Stage II		324 (30.6%)	295 (27.8%)
Stage III		121 (11.4%)	121 (11.4%)
Stage IV		10 (0.9%)	8 (0.8%)
Age, n (%)					0.168	1.9	Chi-squared.test
≤60		312 (28.8%)	289 (26.7%)
>60		229 (21.1%)	253 (23.4%)
Histological type, n (%)					<0.001	68.13	Chi-squared.test
Infiltrating ductal carcinoma		441 (45.1%)	331 (33.9%)
Infiltrating lobular carcinoma		50 (5.1%)	155 (15.9%)
Race, n (%)					0.007	9.94	Chi-squared.test
Asian		33 (3.3%)	27 (2.7%)
Black or African American		71 (7.1%)	110 (11.1%)
White		390 (39.2%)	363 (36.5%)
PR status, n (%)					<0.001		Fisher.test
Negative		245 (23.7%)	97 (9.4%)
Indeterminate		3 (0.3%)	1 (0.1%)
Positive		271 (26.2%)	417 (40.3%)
ER status, n (%)					<0.001		Fisher.test
Negative		193 (18.6%)	47 (4.5%)
Indeterminate		2 (0.2%)	0 (0%)
Positive		324 (31.3%)	469 (45.3%)
HER2 status, n (%)					<0.001	14.1	Chi-squared.test
Negative		279 (38.4%)	279 (38.4%)
Indeterminate		6 (0.8%)	6 (0.8%)
Positive		105 (14.4%)	52 (7.2%)
Molecular subtype, n (%)					<0.001	182.12	Chi-squared.test
Normal		22 (2%)	18 (1.7%)
LumA		187 (17.3%)	375 (34.6%)
LumB		103 (9.5%)	101 (9.3%)
Her2		65 (6%)	17 (1.6%)
Basal		164 (15.1%)	31 (2.9%)
Menopause status, n (%)					0.286	2.5	Chi-squared.test
Pre		115 (11.8%)	114 (11.7%)
Peri		25 (2.6%)	15 (1.5%)
Post		349 (35.9%)	354 (36.4%)
Anatomic neoplasm subdivisions, n (%)					0.522	0.41	Chi-squared.test
Left		287 (26.5%)	276 (25.5%)
Right		254 (23.5%)	266 (24.6%)
Radiation therapy, n (%)					0.521	0.41	Chi-squared.test
No		206 (20.9%)	228 (23.1%)
Yes		275 (27.9%)	278 (28.2%)